Colorectal Cancer
Scandion Oncology A/S focuses on metastatic colorectal cancer, with research centred on treatment-resistant disease and the need for more effective systemic options in advanced gastrointestinal oncology.
- Metastatic colorectal cancer
- Treatment resistance
- Advanced gastrointestinal malignancy
The sponsor’s clinical activity is directed toward patients whose disease has progressed despite prior chemotherapy, reflecting interest in difficult-to-treat oncology settings.
Combination Chemotherapy
Research activity includes the use of FOLFIRI in combination with investigational anticancer therapy, highlighting interest in overcoming acquired resistance through combination treatment strategies.
- FOLFIRI-based regimens
- Combination anticancer therapy
- Acquired resistance
This area reflects a therapeutic focus on enhancing the effectiveness of established chemotherapy backbones in metastatic colorectal cancer.
Safety and Tolerability
The sponsor’s research includes careful assessment of safety, toxicity, and tolerability for new oncology combinations, with attention to treatment exposure in patients with advanced disease.
- Safety profile assessment
- Toxicity monitoring
- Tolerability in advanced cancer
Clinical interest extends to defining how novel agents can be integrated with standard cancer therapy while maintaining acceptable adverse event profiles.
Tumour Response Evaluation
Clinical research also addresses tumour response in solid tumours, with emphasis on measuring objective response in patients receiving therapy for metastatic colorectal cancer.
- Objective response assessment
- Solid tumour evaluation
- Disease control in advanced oncology
This supports the sponsor’s interest in clinical oncology endpoints relevant to treatment benefit in resistant colorectal malignancy.
